InSphero and FDA's NCTR Conduct Groundbreaking Study
InSphero, a distinguished leader in 3D cell culture technology, has made significant strides in drug safety testing. Collaborating with the FDA's National Center for Toxicological Research (NCTR), they have published an extensive benchmarking study on liver toxicity using their revolutionary 3D InSight™ Human Liver Microtissues. This large-scale study assessed the hepatotoxicity of 152 FDA-approved drugs, offering promising insights into early-stage drug safety testing.
Understanding the Importance of Early Detection
Through this study, it was found that approximately 80% of the drugs that were ultimately withdrawn due to liver safety issues were correctly flagged by the innovative 3D liver microtissue platform. This remarkable success underscores the potential of this high-throughput safety technology in identifying dangerous compounds early in the development phase, leading to lower attrition rates in drug development.
A Breakthrough in Predicting Drug-Induced Liver Injury
The study's findings were published in a peer-reviewed journal, showcasing a significant leap forward in predicting drug-induced liver injury (DILI), which often leads to halted projects and substantial financial losses in the pharmaceutical sector. InSphero's unique 3D InSight™ microtissue models effectively combine hepatocytes and other essential liver cell types, producing enhanced biological accuracy. Consequently, while 80% of withdrawn drugs were flagged as toxic, an impressive 89% of the safe compounds were also correctly identified.
Industry Transformation with Human-Based Testing
In light of the FDA Modernization Act 2.0, the study reinforces the necessity for human-centric testing solutions like InSphero’s 3D platform. This shift from animal-based testing not only streamlines drug development but also directs resources to safer and more reliable drug candidates. InSphero's technology aligns with the industry's changing landscape, providing pivotal early drug safety data.
Creating Economic Value Through Predictivity
Utilizing InSphero's microtissue models is predicted to deliver notable economic benefits to drug developers. By identifying hepatotoxic compounds sooner, companies can significantly cut down on preclinical costs, which are often exorbitant. Additionally, this study reinforces the reproducibility of InSphero's liver model, promising reliable outcomes as the research scales up.
A Model for the Future of Drug Safety
Dr. Madhu Nag, Chief Scientific Officer of InSphero, emphasized that their 3D InSight™ Liver Safety Platform melds biological precision with the efficiency and readiness required for industrial applications. This integrated approach supports drug developers in making better-informed decisions earlier during the drug development life cycle. By reducing late-stage failures, InSphero accelerates the timeline for bringing safe drugs to market.
Continuous Learning and Innovation
As industry dynamics evolve, InSphero remains committed to utilizing advanced methods that redefine drug discovery and safety testing. Their innovative technologies enhance the speed at which effective therapies reach patients, illustrating their dedication to research and development.
The future of drug safety testing is promising with breakthroughs like InSphero's 3D microtissues paving the way for a safer and more effective pharmaceutical landscape.
Frequently Asked Questions
What is the significance of the InSphero and FDA's NCTR study?
The study demonstrates the effectiveness of 3D liver microtissues in accurately predicting liver toxicity, paving the way for safer drug development.
How does the 3D InSight™ technology work?
This innovative technology combines hepatocytes from multiple individuals with various liver cells, accurately mimicking liver physiology for enhanced predictability.
What are the economic benefits of using this technology?
By highlighting toxic compounds earlier, drug developers can save on costly preclinical trials and improve overall R&D productivity.
How does this study impact animal testing?
The findings support a shift towards human-based in vitro testing, reducing reliance on animal models and ensuring more relevant results.
Who can benefit from InSphero’s 3D liver safety testing?
Drug developers and pharmaceutical companies looking to enhance the safety of their therapeutics during early development stages can greatly benefit from this innovative platform.
